KRAS mutations are linked to the development of several carcinomas, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC). This evidence concerns the gene KRAS and colorectal carcinoma.